Related Experiment Video

Updated: May 15, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Anticoagulants in patients with atrial fibrillation and end-stage renal disease

K Scott Brimble1, Alistair J Ingram, John W Eikelboom

  • 1Department of Medicine (Nephrology), McMaster University, Hamilton, Ontario, Canada. brimbles@gmail.com

Postgraduate Medicine
|January 17, 2013
PubMed

Insights

Patients with end-stage renal disease (ESRD) and atrial fibrillation (AF) face higher risks. Warfarin may increase bleeding and stroke risk in this population, necessitating further research into safer anticoagulants.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) is a common arrhythmia linked to increased stroke risk.
  • Patients with end-stage renal disease (ESRD) have a higher prevalence of AF.
  • Existing anticoagulant studies often exclude patients with ESRD.

Purpose of the Study:

  • To review the interplay between ESRD, AF, and anticoagulant use for stroke prevention.
  • To evaluate the risks and benefits of anticoagulation in ESRD patients with AF.

Main Methods:

  • Systematic literature search of Medline and Embase databases.
  • Inclusion of identified review articles and their bibliographies.
  • Analysis of observational data and current guidelines.

Main Results:

  • ESRD is an independent risk factor for AF.
  • AF in ESRD patients increases stroke risk, though less than in the general population.
  • Warfarin use in ESRD patients is associated with increased bleeding and potentially hemorrhagic stroke, with unclear benefits for ischemic stroke prevention.

Conclusions:

  • Warfarin may exacerbate bleeding risks and vascular calcification in ESRD patients.
  • Current guidelines recommend warfarin only for secondary stroke prevention in ESRD with AF.
  • Randomized controlled trials are essential to determine optimal anticoagulation strategies for ESRD patients with AF.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...